Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 16/20 | 0.73 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19228428 | 1.00 | RIPK1 (0.73) | RIPK1THRBLMNAPOLBMAPT | |
| SCHEMBL19228429 | 1.00 | RIPK1 (0.73) | RIPK1THRBLMNAPOLBMAPT | |
| SCHEMBL19228427 | 0.91 | RIPK1 (0.76) | RIPK1THRBLMNAPOLBMAPT | |
| SCHEMBL19805406 | 0.84 | RIPK1 (1.00) | RIPK1THRBLMNAPOLB | |
| SCHEMBL29415770 | 0.84 | RIPK1 (1.00) | RIPK1THRBLMNAPOLB | |
| SCHEMBL19228316 | 0.84 | RIPK1 (1.00) | RIPK1THRBLMNAPOLB | |
| SCHEMBL29415638 | 0.84 | RIPK1 (1.00) | RIPK1THRBLMNAPOLB | |
| SCHEMBL20050206 | 0.83 | RIPK1 (0.53) | RIPK1 | |
| SCHEMBL20903989 | 0.83 | RIPK1 (0.53) | RIPK1 | |
| SCHEMBL20903990 | 0.83 | RIPK1 (0.53) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-9896458-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885THRB 3189/4885LMNA 1620/4885 |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885THRB 3189/4885LMNA 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.